

USSN 09/551,977

II. REMARKS

Claims 1-37 were pending. Pursuant to a Restriction Requirement, claims 1-16, 18, and 24-37 were withdrawn from consideration.

Applicants gratefully acknowledge Examiner Li's telephone call to discuss the case. During this call, it was agreed that the foregoing amendments to the claims and specification would place the case in condition for allowance.

In particular, the specification has been amended to insert sequence identification numbers were appropriate, particularly on pages 34-35 and 37. Claims 1-16, 18 and 24-37 have been canceled by amendment herein and the dependencies of claims 19, 21, 22 and 23 have been corrected. Applicants reserve the right to file a continuation or divisional application directed to the subject matter of the canceled claims at any time during the pendency of this application. In claim 17, Applicants have replaced the language "comprising one or more" with the equivalent term "comprising an," as described throughout the application as filed, for example, on page 5, lines 4-9 and in the original claims. (See, *PPG Indus v. Guardian Indus Corp.* 48 USPQ2d 1351, 1353 (Fed. Cir. 1998); *Elkay Mfg. Co. v. Ebcu Mfg. Co.*, 52 USPQ2d 1109, 1112, 1353 (Fed. Cir. 1999); *AbTox, Inc. v. Exitron Corp.*, 43 USPQ2d 1545, 1548 (Fed. Cir. 1997); Robert Faber ed., *Landis on Claim Drafting* 531 (3 ed. 1990) establishing that the term "an" in patent parlance carries the meaning of "one or more" in open-ended claims containing the transitional phrase "comprising").

Since the pending claims define an invention that is novel and fully enabled and defined by the specification, Applicant requests that the application proceed to allowance.

Please direct all further communications regarding this application to:

Marcella Lillis, Esq.
CHIRON CORPORATION
Intellectual Property - R440
P.O. Box 8097
Emeryville, CA 94662-8097
Telephone: (510) 923-8406; Facsimile: (510) 655-3542

Respectfully submitted,

Date: 21 Jan 03

By: Dahna S. Pasternak
Dahna S. Pasternak
Registration No. 41,411

Cooley Godward LLP
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306
Tel. (650) 843-5608; Fax. (650) 857-0663

631615 v1/PA
DJCV011.DOC

USSN 09/551,977

Version Showing Changes Made**In the specification:**

The text on starting on line 3 of page 34 and ending on line 7 of page 35 has been amended as follows:

-- Synthesis of cDNA was accomplished by PCR amplification, using the primer sets shown below (Sindbis nucleotide numbering indicated for each primer):

1	<u>CCACAAAGCTT</u> GATCTAATGTACCAGCCTGATGC	11472-11450	(SEQ ID NO:3)
1.1	<u>CCACGAATT</u> CAGCCAGATGAGTGAGGC	10364-10381	(SEQ ID NO:4)
2	<u>CCACAAAGCTT</u> CAATTGACGTACGCCCTCAC	10394-10375	(SEQ ID NO:5)
2.1	<u>CCACGAATT</u> CATATGGGGAAATCATGAGCC	9614-9634	(SEQ ID NO:6)
3	<u>CCACAAAGCTT</u> CATAGACCCTCACTGGCTC	9648-9630	(SEQ ID NO:7)
3.1	<u>CCACGAATT</u> CAAGATTAGCACCTCAGGACC	8878-8899	(SEQ ID NO:8)
4	<u>CCACAAAGCTT</u> CTACACGGCCTGAGGTGC	8908-8887	(SEQ ID NO:9)
4.1	<u>CCACGAATT</u> CGTCGATCATGGATAACTCC	8294-8315	(SEQ ID NO:10)
5	<u>CCACAAAGCTT</u> CGCCACCGAGGAC	8347-8334	(SEQ ID NO:11)
5.1	<u>CCACGAATT</u> CACTGCCATGTGGAGGCC	7797-7814	(SEQ ID NO:12)
6	<u>CCACCTCGAG</u> TTTACCCAACCTAACAGCC	7368-7348	(SEQ ID NO:13)
6.1	<u>CCACGAGCT</u> CGCGACATTCAATGTCGAATGC	6426-64467	(SEQ ID NO:14)
7	<u>CCACCTCGAG</u> GAACTCCTCCCAATACTCGTC	6488-6468	(SEQ ID NO:15)
7.1	<u>CCACGAGCT</u> CGACCTTGGAGCGCAATGTCC	5843-5862	(SEQ ID NO:16)
8	<u>CCACCTCGAG</u> TTCGACGTGTCGAGCACC	5900-5882	(SEQ ID NO:17)
8.1	<u>CCACGAGCT</u> CGACCATGGAAGCAATCCGC	4814-4832	(SEQ ID NO:18)
9	<u>CCACCTCGAG</u> GACGACGGGTTATGGTCGAC	4864-4845	(SEQ ID NO:19)
9.1	<u>CCACGAGCT</u> CCACGGAGACAGGCACCGC	4246-4264	(SEQ ID NO:20)
10	<u>CCACCTCGAG</u> GATCACTTCTTCCTAGGCAC	4299-4277	(SEQ ID NO:21)
10.1	<u>CCACGAGCT</u> CGAACTCTCCGTAGATTCC	3407-3427	(SEQ ID NO:22)

USSN 09/551,977

11	<u>CCACCTCGAGATCAAGTTGTGCCCTTCC</u>	3464-3445 (<u>SEQ ID NO:23</u>)
11.1	<u>CCACGAGCTCCCAGGGATATCATCCTGAC</u>	2742-2761 (<u>SEQ ID NO:24</u>)
12	<u>CCACCTCGAGGCTGTCATTACTCATGTCCG</u>	2825-2804 (<u>SEQ ID NO:25</u>)
12.1	<u>CCACGAGCTCGAACCGCAAACATACACATTGC</u>	1976-1999 (<u>SEQ ID NO:26</u>)
13	<u>CCACCTCGAGCTTGTACTGCTCCTCTTCTG</u>	2042-2023 (<u>SEQ ID NO:27</u>)
13.1	<u>CCACGAGCTCGGAGAACGGGTATCGTTCC</u>	1029-1047 (<u>SEQ ID NO:28</u>)
14	<u>CCACCTCGAGCCGGGATGTACGTGCAC</u>	1069-1052 (<u>SEQ ID NO:29</u>)
14.1	<u>CCACGAGCTCATTGACGGCGTAGTACACAC</u>	1-20 (<u>SEQ ID NO:30</u>)--

The text on lines 3 through 13 of page 37 has been amended as follows:

--In addition, cDNA clones representing the subgenomic promoter region and 3'-end nontranslated regions also were generated using the following primer pairs:

YSIN1F

5'-GATTCGGTTACTTCCACAGC (SEQ ID NO:31)

YSIN1R

5'-ACTGACGGCTGTGGTCAGTT (SEQ ID NO:32)

YSIN2F

5'-GATGTACTTCCGAGGAAC TG (SEQ ID NO:33)

YSIN2R

5'-CCACAAGCTTGAAATGTTAAAAACAAAATTTGT (SEQ ID NO:34)--

In the claims:

Claims 1-16, 18 and 24-37 have been canceled, without prejudice or disclaimer.

17. (Thrice Amended) A recombinant alphavirus particle which infects human dendritic cells, said recombinant alphavirus particle comprising an [one or more] amino acid [mutations] mutation at about amino acids 158 through 162 of the E2 glycoprotein as compared to wild-type, with the proviso that said recombinant alphavirus particle is not derived from ATCC # VR-2526.

19. (Amended) The recombinant alphavirus particle of claim 17 [or 18] wherein said alphavirus is a Sindbis virus.

USSN 09/551,977

21. (Amended) The recombinant alphavirus particle according to claim 17 [or 18] wherein said alphavirus is Semliki Forest virus.
22. (Amended) The recombinant alphavirus particle according to claim 17 [or 18] wherein said alphavirus is Ross River virus.
23. (Amended) The recombinant alphavirus particle according to claim 17 [or 18] wherein said alphavirus is Venezuelan equine encephalitis virus.

USSN 09/551,977

Currently Pending Claims

1 to 16. Canceled.

17. (Thrice Amended) A recombinant alphavirus particle which infects human dendritic cells, said recombinant alphavirus particle comprising an amino acid mutation at about amino acids 158 through 162 of the E2 glycoprotein as compared to wild-type, with the proviso that said recombinant alphavirus particle is not derived from ATCC # VR-2526.

18. Canceled.

19. (Amended) The recombinant alphavirus particle of claim 17 wherein said alphavirus is a Sindbis virus.

20. The recombinant alphavirus particle according to claim 19 wherein said alphavirus has an amino acid substitution at E2 residue 160, as compared to wild-type Sindbis virus.

21. The recombinant alphavirus particle according to claim 17 wherein said alphavirus is Semliki Forest virus.

22. The recombinant alphavirus particle according to claim 17 wherein said alphavirus is Ross River virus.

23. The recombinant alphavirus particle according to claim 17 wherein said alphavirus is Venezuelan equine encephalitis virus.

24 to 37. Canceled.